|
|
|
|
| LEADER |
05673nma a2201513 u 4500 |
| 001 |
EB002159019 |
| 003 |
EBX01000000000000001297134 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230515 ||| eng |
| 020 |
|
|
|a books978-3-0365-7250-5
|
| 020 |
|
|
|a 9783036572512
|
| 020 |
|
|
|a 9783036572505
|
| 100 |
1 |
|
|a Jervis, Peter John
|
| 245 |
0 |
0 |
|a Hydrogels in Regenerative Medicine and Other Biomedical Applications
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (358 p.)
|
| 653 |
|
|
|a myoblast
|
| 653 |
|
|
|a PNIPAM-based graft copolymers
|
| 653 |
|
|
|a 3d printing
|
| 653 |
|
|
|a dehydrodipeptide
|
| 653 |
|
|
|a LCST adjustment
|
| 653 |
|
|
|a rheological properties
|
| 653 |
|
|
|a h-osteoblasts
|
| 653 |
|
|
|a synthetic mimic of heparin
|
| 653 |
|
|
|a testicular tissue transplantation
|
| 653 |
|
|
|a poly(sodium-4-styrenesulfonate)
|
| 653 |
|
|
|a PVA
|
| 653 |
|
|
|a fusion
|
| 653 |
|
|
|a decellularization
|
| 653 |
|
|
|a necrosis inhibitor
|
| 653 |
|
|
|a triclosan
|
| 653 |
|
|
|a PDGF
|
| 653 |
|
|
|a in vitro model
|
| 653 |
|
|
|a Technology: general issues / bicssc
|
| 653 |
|
|
|a functionalization
|
| 653 |
|
|
|a peptidomimetic
|
| 653 |
|
|
|a shear-responsive
|
| 653 |
|
|
|a sol-gel transition
|
| 653 |
|
|
|a decellularized cartilage matrix
|
| 653 |
|
|
|a tissue engineering
|
| 653 |
|
|
|a tunable lens
|
| 653 |
|
|
|a poly(vinyl alcohol)
|
| 653 |
|
|
|a phononic crystal
|
| 653 |
|
|
|a cobalt-substituted hydroxyapatite
|
| 653 |
|
|
|a thermo-responsive
|
| 653 |
|
|
|a hydrogels
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a chronic lymphocytic leukemia
|
| 653 |
|
|
|a XPS
|
| 653 |
|
|
|a nanoparticles
|
| 653 |
|
|
|a sodium alginate
|
| 653 |
|
|
|a tissue bio-adhesive
|
| 653 |
|
|
|a polyvinyl alcohol
|
| 653 |
|
|
|a adipose tissue regeneration
|
| 653 |
|
|
|a Chit-RGD
|
| 653 |
|
|
|a spermatogonia stem cells
|
| 653 |
|
|
|a drug delivery
|
| 653 |
|
|
|a cellulose
|
| 653 |
|
|
|a methacrylate glycol chitosan
|
| 653 |
|
|
|a acute wounds
|
| 653 |
|
|
|a burn wounds
|
| 653 |
|
|
|a antibacterial ability
|
| 653 |
|
|
|a 3D scaffold
|
| 653 |
|
|
|a marjoram oil
|
| 653 |
|
|
|a carpal tunnel syndrome
|
| 653 |
|
|
|a biocompatibility
|
| 653 |
|
|
|a microenvironment mimicking matrix
|
| 653 |
|
|
|a angiogenesis
|
| 653 |
|
|
|a diabetic foot ulcers
|
| 653 |
|
|
|a injectability
|
| 653 |
|
|
|a VEGF
|
| 653 |
|
|
|a vascular maturity
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a B cell survival
|
| 653 |
|
|
|a human gingival fibroblast
|
| 653 |
|
|
|a ultrasound
|
| 653 |
|
|
|a diabetic wounds
|
| 653 |
|
|
|a chitosan
|
| 653 |
|
|
|a chronic wounds
|
| 653 |
|
|
|a deep detection
|
| 653 |
|
|
|a wound healing
|
| 653 |
|
|
|a NEXAFS
|
| 653 |
|
|
|a human hair keratin
|
| 653 |
|
|
|a Biotechnology / bicssc
|
| 653 |
|
|
|a beta-cyclodextrin
|
| 653 |
|
|
|a hemostatic dressing
|
| 653 |
|
|
|a alginate
|
| 653 |
|
|
|a fertility preservation
|
| 653 |
|
|
|a PLCL
|
| 653 |
|
|
|a smart materials
|
| 653 |
|
|
|a myogenic differentiation
|
| 653 |
|
|
|a entrapment neuropathy
|
| 653 |
|
|
|a bioprinting
|
| 653 |
|
|
|a Chit-HVP
|
| 653 |
|
|
|a antibacterial and antioxidant wound dressing
|
| 653 |
|
|
|a poly(2-hydroxyethyl methacrylate)
|
| 653 |
|
|
|a supramolecular
|
| 653 |
|
|
|a betamethasone
|
| 653 |
|
|
|a fibrinogen
|
| 653 |
|
|
|a extracellular matrix
|
| 653 |
|
|
|a thiol-ene cross-linking
|
| 653 |
|
|
|a antibacterial
|
| 653 |
|
|
|a ultrasonic detection
|
| 653 |
|
|
|a RGDS
|
| 653 |
|
|
|a kaolin
|
| 653 |
|
|
|a injectable hydrogel
|
| 653 |
|
|
|a biomaterials
|
| 653 |
|
|
|a dECM hydrogel
|
| 653 |
|
|
|a hybrid hydrogel
|
| 653 |
|
|
|a focal adhesion kinase (FAK)
|
| 653 |
|
|
|a hydrogel
|
| 653 |
|
|
|a wound dressings
|
| 653 |
|
|
|a cartilage tissue engineering
|
| 653 |
|
|
|a animal model
|
| 700 |
1 |
|
|a Jervis, Peter John
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-7250-5
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/100009
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/7102
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 363
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 600
|
| 082 |
0 |
|
|a 620
|
| 520 |
|
|
|a Great strides have been made in the area of hydrogel science since the first hydrogels were described in the 1960s. Hydrogels usually consist of three-dimensional matrices of hydrophilic polymers, held together by chemical or physical crosslinks, or supramolecular assemblies of small amphiphilic molecules. The gelation process occurs in response to a physical or chemical stimulus, such as temperature, pH, electric or magnetic field, enzymatic modification, light, and others. Consisting of mainly water molecules, they represent a unique class of materials, with many applications such as cell therapeutics, cartilage/bone regeneration, sustained drug release and drug delivery systems, tissue engineering, and 3D bioprinting. Despite these great strides, there is still much more to discover in this area. This Special Issue is focused on the use of hydrogels in tissue and bone regeneration. Hydrogels are particularly suited for this purpose as their physical characteristics resemble that of the extracellular matrix; as such, they have found applications as an extracellular medium for cancer cells, stem cells, and neuronal cells. This Special Issue also includes research papers on the other biomedical applications of hydrogels.
|